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Abstract 
[PURPOSE] Angiogenesis is crucial to malignant glioma growth. Therefore, 
antiangiogenic therapy represents as new, promising therapeutic modality for malignant 
gliomas. This study designed to define the malignant glioma cases most suitable for 
anti-angiogenic therapy in human and to demonstrate the efficacy of anti-angiogenic 
therapy in the animal. 
[METHODS & RESULTS] In human malignant glioma samples (24 glioblastomas, 13 
anaplastic astrocytomas), the protein expression of most potent angiogenic factor, 
VEGF and its specific natural inhibitor, soluble Flt-1 as well as vessel architectures, 
including vessel density, area, and diameter were evaluated. Among these, VEGF>1000 
ng/ml, VEGF/soluble Flt1 ratio >1, vessel density >30, vessel area >7% were prognostic 
factors for malignant gliomas. Based on these results, we demonstrated three different 
anti-angiogenic experiments targeted to inhibit VEGF expression in human malignant 
glioma (U87) mouse model. 1) Anti-VEGF neutralized antibody intraperitoneal 
injection, 2) interferon-beta intramusclar injection, and 3) an endogenous non-specific 
angiogenesis inhibitor, thrombospondin-1, transfection into glioma cells caused 
inhibition of VEGF secretion and/or mRNA expression and resulted in glioma growth 
inhibition of 70%, 84%, and 50% respectively compared to control. 
Takano et al. 3 
[CONCLUSION] We conclude that malignant gliomas with high degree of VEGF 
expression and vessel area are good candidate for anti-angiogenic therapy, especially 
when designed to target to inhibit VEGF expression. 
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Introduction 
Angiogenesis is crucial to malignant glioma growth. 1-3 Therefore, antiangiogenic 
therapy represents as promising therapeutic modality for malignant gliomas.4 Current 
defined endogenous angiogenic stimulators and inhibitors in neoplasms have been well 
described.5 Especially the balance between stimulators and inhibitors regulate 
angiogenesis of the tumors, resulting tumor growth.6 Almost all of these factors have 
been investigated for gliomas and these factors should be designed for glioma 
anti-angiogenesis therapy. The evidence of glioma anti-angiogenesis therapy is 
described in many animal experiments combined with and without chemotherapy, 
where showed dramatic inhibition of glioma growth.7,8 These include many anti-VEGF 
strategies, for example, antisence, antibody, receptor antibody etc.9 Interestingly, four 
angiogenesis inhibitors, interferon-beta, marimastat, suramin, thalidomide, are now 
under the clinical trials. However, the results of these clinical trials have been limited. 
Further studies are needed to improve the efficacy of the therapy. This study designed to 
define the malignant glioma cases most suitable for anti-angiogenic therapy in human 
and to demonstrate the efficacy of anti-angiogenic therapy in the animal. 
 
Materials and Methods 
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I. Angiogenic profiles of gliomas 
Human malignant glioma samples (24 glioblastomas, 13 anaplastic astrocytomas) were 
stored at -80 degree. The protein expression of most potent angiogenic factor, VEGF 
and its specific natural inhibitor, soluble Flt-1 were measured with ELISA (R&D 
systems). Vessel architectures, including vessel density, area, and diameter were 
measured by CD31 stained sections using Windroof morphometry software (Sankou 
Shoji). By marking each vessel outline, vessel density per 0.13mm2, vessel occupied 
area, vessel diameter, vessel perimeter, and vessel roundness were measured on three 
different areas. MIB-1(Immunotech) and p53 (DO7) positivities were measured. Based 
on these profiles, prognostic factors of malignant gliomas were investigated. 
II. Anti-angiogenic therapy for U87 mouse glioma model 
We designed three different anti-angiogenic experiments targeted to inhibit VEGF 
expression in human malignant glioma, U87 mouse model.9 First, anti-VEGF 
neutralizing antibody experiment. Second, an endogenous non-specific angiogenesis 
inhibitor, thrombospondin-1, transfection into glioma cells, U87. Third, interferon-beta 
intraperitoneal injection. In each experiment, tumor growth, angiogenic profiles, and 
VEGF expression were evaluated. 
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Results 
I. Angiogenic profiles and their relation to survival of gliomas 
Our treatment strategy for malignant gliomas is total or subtotal removal, following by 
40 Gy whole brain and 20 Gy local boast irradiation combined with PAV (procarbazine 
ACNU, Vincristine) chemotherapy and interferon-β. At the recurrence, PE (cisplatin, 
etoposide) chemotherapy and / or immunotherapy, including locolesional natural killer 
or cytotoxic T lymphocyte injection were carried out. Median survival rate of all 
malignant gliomas were 19.2 mo, (glioblastoma 11.2 mo, and anaplastic astrocytoma 
30.9 mo). 
VEGF concentration and sFlt-1 concentration more than 1000 pg/mg were prognostic 
factors. VEGF/ sFlt-1 ratio over than 1 was a strongest prognostic factor among each 
factor. Median survival time was 11.3 month for ratio over 1 and 28.7 month for ratio 
under 1 (Table). These results suggest the balance of stimulators and inhibitors of 
angiogenesis is especially important for the angiogenic evaluation of malignant gliomas. 
Other angiogenic parameters, vessel density more than 30, and vessel area more than 
7% also predicted malignant glioma survival (Table). 
 
II. Anti-angiogenic therapy for U87 mouse glioma model 
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1) Anti-VEGF neutralizing antibody experiment 
Intraperitoneal injection of VEGF antibody 100 µg, twice a week for 4 weeks, inhibited 
glioma growth with subcutaneous model (Figure 1) and prolonged survival of 
intracranial glioma bearing mouse (data not shown).  
2) Thrombospondin-1 transfection 
Thrombospopndin-1 cDNA transfected into U87 using fugene6. Thrombospondin-1 
transefectant secreted not only a large amount of thrombospondin in the conditioned 
medium but also a decreased amount of VEGF in the conditioned medium compared to 
parent and control glioma cells. The growth of the transfectant in vivo in the mouse 
subcutaneous model was significantly slow compared to control (Figure 2). Western 
blot analysis of transfectant glioma tissues shows decreased expression of VEGF as well 
as increased expression of thrombospondin-1 compared to control glioma tissues (data 
not shown). 
3) Interferon-beta intraperitoneal injection 
Low dose (1x105 unit every day for 15 days) and high dose (5x105 unit) interferon-beta 
systemic treatment significantly inhibited glioma subcutaneous growth. After 
discontinuation of the treatment, glioma growth re-started, suggesting the growth 
inhibitory effect of interferon-beta is cytostatic, not cytosidal (Figure 3A). In the glioma 
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tissues, interferon-beta treatment remarkably up-regulated the protein expression of 
IP-10, an endogenous inhibitor of angiogenesis and down-regulated the VEGF protein 
expression (Figure 3B).  
Discussion 
In this study, we demonstrated 1) angiogenic profiles of malignant gliomas which are 
related to prognosis and 2) three types of VEGF targeting anti-angiogenesis 
experimental therapy for malignant gliomas.  
1) Angiogenic profile of malignant gliomas 
Importance of angiogenesis of malignant gliomas has been demonstrated by many 
investigations. However, definite value of the degree of angiogenesis is variable 
between the methods which measure the angiogenesis. Therefore, which malignant 
gliomas are most suitable for the anti-angiogenesis therapy is not clear. Among the 
parameters of angiogenesis, VEGF10 and its specific inhibitor, soluble Flt-1 are 
important. Soluble Flt-1 is a soluble form of VEGF receptor-1 called Flt1. soluble Flt1 
is a part of intracellular domain of Flt1 and is existed in the tissue with the soluble form. 
Because soluble Flt-1 has VEGF binding site, it inhibits VEGF binding to the receptor.11 
In our study, VEGF>1000pg/mg, VEGF/sFlt-1 ratio>1, vessel density >30 / 0.13mm2, 
vessel area >7% were prognostic factors for malignant gliomas. Especially, VEGF/ 
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sFLT-1 ratio was the strongest prognostic factor, meaning not only the amount of 
stimulators but also the balance with a specific stimulator (e.g. VEGF) and its inhibitor 
(e.g. sFlt-1) is more reliable. Malignant gliomas which possess these angiogenic values 
should be suitable candidates for VEGF targeting anti-angiogenesis therapy.   
2) VEGF targeting anti-angiogenesis therapy 
Next, anti-VEGF antibody intraperitoneal injection, thrombospondin-1 transfection into 
glioma cell, and interferon-beta intraperitoneal injection caused inhibition of VEGF 
expression (secretion and/or mRNA level), and resulted in glioma growth inhibition 
compared to control 
VEGF neutralizing antibody is now clinically relevant for colon cancer and renal cell 
carcinoma.12 These data as well as our data promptly us to use these compounds as 
anti-angiogenesis molecules for malignant gliomas. Anti-angiogenic function of 
Thrombospondin-1 has been investigated for a long time.13 In vitro, TSP-1 transfectant 
was inhibited the secretion of VEGF and in vivo, TSP-1 transfectant glioma tissues had 
few VEGF expression compared to control. This molecular link between TSP1 and 
VEGF is quite new finding and promising the possibility of anti-angiogenic gene 
therapy14 utilizing TSP1 molecule. Interferon-β has been clinically used systemically 
and genetically.15,16 Our experimental result clearly its anti-angiogenesis effect and its 
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cytostatic, not cytosidal, effect. We emphasize the target molecule of interferon-β is 
VEGF as well as bFGF17 as a stimulator and IP10 as an inhibitor of angiogenesis in the 
view point of anti-angiogenesis. 
We conclude that malignant gliomas with high degree of VEGF expression and vessel 
area are good candidate for anti-angiogenic therapy. Targeting to inhibit VEGF 
expression is a promising therapy for malignant gliomas. 
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Figure legend 
Figure 1  anti-VEGF antibody treatment (100 µg intraperitoneal injection, every 4 days, 
8 times) inhibited U87 subcutaneous glioma growth. * p < 0.01 compared to control  
 
Figure 2   The subcutaneous growth of Thrombospondin-1 transfected U87 glioma 
cells is significantly (p < 0.01) inhibited compared to ones of vector-transfected and 
non-transfected parent cells. 
 
Figure 3  A. Intereferon-β treatment (low and high dose intraperitoneal injection, every 
day for 14 days) significantly (p < 0.01) inhibited U87 subcutaneous glioma growth. 
After discontinuation of the treatment (NO INF-β), tumor restarted to grow, meaning 
the cytostatic effect of the inhibition.  B. Western blotting with IP10 and VEGF of 
Glioma tissue treated with interferon-β. Interferon-β treatment increased expression of 
interferon-induced protein 10 (IP10) and decreased expression of VEGF. 
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Figure 3A 
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Figure 3B 
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<20% 23 21.1
 
Parameter number MST mo p value
univariate
VEGF >1000 20 11.8
(pg/mg) <1000 17 24.8
sFlt1 >1000 6 9.3
(pg/mg) <1000 31 21
Ratio >1 24 11.3
<1 13 28.7
Density >30 22 12.3
<30 15 24.6
Area >7% 14 11.6
<7% 23 23.1
Pathology GBM 24 11
AA 13 28.8
MIB-1 >20% 12 9.3
<20% 25 20.6
p53 >20% 14 13.4
0.0025
0.0145
<0.0001
0.0177
0.0134
<0.0001
0.1742
0.284
Table   Angiogenic profiles relating to survival of malignant gliomas 
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Figure 3A 
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